Local Tolerability of AN2728 Topical Ointment, 2% in Sensitive Areas in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions
- Sponsors Anacor Pharmaceuticals
- 22 Jun 2016 Results published in the American Journal of Clinical Dermatology
- 07 Feb 2012 Status changed from recruiting to completed, according to an Anacor Pharmaceuticals media release.
- 06 Dec 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12611001128987).